The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

Antonio Gasbarrini, Loris Riccardo Lopetuso, Marco Napoli, Gianenrico Rizzatti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

Introduction: The gastrointestinal tract acts as a functional unit organized as a semipermeable multilayer system, in which commensal gut microbiota represents the anatomical barrier. Recently, several studies have highlighted the involvement of gut microbiota in inflammatory bowel diseases (IBD) pathogenesis, in sustaining gut barrier chronic inflammation, and in conditioning disease course and therapeutical response. This evidence provides a rationale for treating patients with gut microbiota modifiers. Among these, Rifaximin represents a non-traditional antibiotic able to act as a ‘eubiotic’ on intestinal barrier. Area covered: The purpose of this narrative review is to explore the impact of Rifaximin on gut barrier and gut microbiota in IBD, in particular in Crohn’s disease (CD), and to analyze its potential therapeutic applications. Expert opinion: The possibility of a beneficial activity of Rifaximin in chronic intestinal inflammation and CD has been debated and evaluated with different studies having obtained promising but still preliminary data. Larger trials are therefore needed. This gut-specific antibiotic could represent an alternative to systemic antibiotics thanks to its favorable safety profile and promising efficacy data. Rifaximin could exert, when appropriate, a synergic effect with immunomodulators in IBD, acting on both the microbial and the immunological sides of gut barrier impairment.
Lingua originaleEnglish
pagine (da-a)543-551
Numero di pagine9
RivistaExpert Opinion on Investigational Drugs
Volume27
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • Animals
  • Anti-Infective Agents
  • Crohn Disease
  • Crohn’s disease
  • Drug Synergism
  • Gastrointestinal Agents
  • Gastrointestinal Microbiome
  • Humans
  • IBD
  • Immunologic Factors
  • Inflammation
  • Inflammatory Bowel Diseases
  • Pharmacology
  • Pharmacology (medical)
  • Rifamycins
  • Rifaximin
  • chronic inflammation
  • gut barrier
  • gut microbiota
  • inflammatory bowel disease

Fingerprint Entra nei temi di ricerca di 'The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease'. Insieme formano una fingerprint unica.

Cita questo